Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia
NCT04774744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 157
Last updated 2023-09-18
Summary
This trial studies the effect of a digital health coaching program on self-efficacy and patient reported outcomes of patients with acute myeloid leukemia or chronic lymphocytic leukemia that is newly diagnosed. A digital health coaching program may help leukemia patients report information about their health while receiving treatment, which may lead to improvement in overall health.
Conditions
Interventions
- OTHER
-
Educational Intervention
Receive digital health coaching program
- OTHER
-
Questionnaire Administration
Ancillary studies
- OTHER
-
Supportive Care
Receive standard of care support services
Sponsors & Collaborators
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Courtney DiNardo · M.D. Anderson Cancer Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-03-17
- Primary Completion
- 2023-09-13
- Completion
- 2023-09-13
Countries
- United States
Study Locations
More Related Trials
-
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
NCT06446661 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Novel Digital Application for Patients With Acute Leukemia
NCT06472128 ·Status: RECRUITING ·Phase: NA
-
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
NCT03090477 ·Status: COMPLETED ·Phase: NA
-
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT06697600 ·Status: RECRUITING ·Phase: NA
-
An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
NCT01446081 ·Status: COMPLETED ·Phase: PHASE2
-
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
NCT00061945 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60
NCT02234037 ·Status: TERMINATED ·Phase: PHASE1
-
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865 ·Status: COMPLETED ·Phase: PHASE2
-
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01235572 ·Status: COMPLETED ·Phase: PHASE2
-
Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia
NCT02842112 ·Status: COMPLETED
-
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
NCT03568994 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916 ·Status: COMPLETED
-
AML Expressive Writing
NCT04006496 ·Status: TERMINATED ·Phase: NA
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
NCT05035706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Reduce Sedentary Time in Acute Lymphoblastic Leukemia
NCT06182163 ·Status: COMPLETED ·Phase: NA
-
COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT03595787 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
NCT00422591 ·Status: COMPLETED ·Phase: PHASE2
-
Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome
NCT00394381 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
NCT03488862 ·Status: COMPLETED
-
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
NCT03672539 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
NCT03318900 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
NCT00474006 ·Status: COMPLETED ·Phase: PHASE3
-
Feasiblity and Safety of Home-based Intensive Chemotherapy
NCT04904211 ·Status: COMPLETED ·Phase: NA
-
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
NCT07094750 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies
NCT00038051 ·Status: COMPLETED ·Phase: PHASE1